Raffles Medical Group Ltd Logo

Raffles Medical Group Ltd

BSL.SI

(1.2)
Stock Price

0,87 SGD

4.06% ROA

5.96% ROE

27.94x PER

Market Cap.

1.671.590.025,00 SGD

9.81% DER

2.67% Yield

8.67% NPM

Raffles Medical Group Ltd Stock Analysis

Raffles Medical Group Ltd Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Raffles Medical Group Ltd Fundamental Stock Analysis
# Analysis Rating
1 Revenue Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

2 Dividend

Investors can take comfort in the company's unwavering commitment to dividends, as it has consistently distributed payouts over the past five years, ensuring a reliable income stream.

3 Net Profit Growth

The net profit of this company has shown steady growth over the past three years, highlighting its positive financial trajectory and making it an appealing choice for potential investors.

4 ROE

Unidentified ROE

5 ROA

Unidentified ROA

6 PBV

Unidentified ROA

7 DER

Unidentified DER

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Graham Number

Unidentified Graham Number

10 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Raffles Medical Group Ltd Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Raffles Medical Group Ltd Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Raffles Medical Group Ltd Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Raffles Medical Group Ltd Revenue
Year Revenue Growth
2001 76.304.000
2002 87.997.000 13.29%
2003 99.105.000 11.21%
2004 101.456.000 2.32%
2005 112.898.000 10.13%
2006 134.248.000 15.9%
2007 168.659.000 20.4%
2008 200.769.000 15.99%
2009 218.610.000 8.16%
2010 239.123.000 8.58%
2011 272.783.000 12.34%
2012 311.633.000 12.47%
2013 340.989.000 8.61%
2014 374.641.000 8.98%
2015 410.535.000 8.74%
2016 473.608.000 13.32%
2017 477.583.000 0.83%
2018 489.135.000 2.36%
2019 522.038.000 6.3%
2020 568.203.000 8.12%
2021 723.791.000 21.5%
2022 766.537.000 5.58%
2023 708.032.000 -8.26%
2024 731.380.000 3.19%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Raffles Medical Group Ltd Research and Development Expenses
Year Research and Development Expenses Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Raffles Medical Group Ltd General and Administrative Expenses
Year General and Administrative Expenses Growth
2001 45.020.000
2002 50.000.000 9.96%
2003 56.748.000 11.89%
2004 56.688.000 -0.11%
2005 61.523.000 7.86%
2006 69.284.000 11.2%
2007 85.939.000 19.38%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Raffles Medical Group Ltd EBITDA
Year EBITDA Growth
2001 2.754.000
2002 9.355.000 70.56%
2003 12.910.000 27.54%
2004 13.948.000 7.44%
2005 15.667.000 10.97%
2006 20.768.000 24.56%
2007 32.436.000 35.97%
2008 45.643.000 28.94%
2009 52.400.000 12.9%
2010 60.321.000 13.13%
2011 66.932.000 9.88%
2012 74.723.000 10.43%
2013 103.555.000 27.84%
2014 90.985.000 -13.82%
2015 94.509.000 3.73%
2016 97.749.000 3.31%
2017 96.014.000 -1.81%
2018 103.591.000 7.31%
2019 109.210.000 5.15%
2020 127.003.000 14.01%
2021 162.761.000 21.97%
2022 257.121.000 36.7%
2023 132.889.999 -93.48%
2024 120.010.000 -10.73%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Raffles Medical Group Ltd Gross Profit
Year Gross Profit Growth
2001 67.515.000
2002 78.938.000 14.47%
2003 86.970.000 9.24%
2004 89.513.000 2.84%
2005 99.188.000 9.75%
2006 117.669.000 15.71%
2007 149.287.000 21.18%
2008 165.231.000 9.65%
2009 178.061.000 7.21%
2010 195.018.000 8.7%
2011 221.298.000 11.88%
2012 250.511.000 11.66%
2013 278.127.000 9.93%
2014 300.444.000 7.43%
2015 329.394.000 8.79%
2016 381.958.000 13.76%
2017 383.957.000 0.52%
2018 389.617.000 1.45%
2019 411.069.000 5.22%
2020 432.428.000 4.94%
2021 580.521.000 25.51%
2022 639.981.000 9.29%
2023 315.935.000 -102.57%
2024 328.550.000 3.84%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Raffles Medical Group Ltd Net Profit
Year Net Profit Growth
2001 -7.508.000
2002 4.506.000 266.62%
2003 8.060.000 44.09%
2004 9.481.000 14.99%
2005 11.958.000 20.71%
2006 15.713.000 23.9%
2007 35.863.000 56.19%
2008 31.547.000 -13.68%
2009 37.882.000 16.72%
2010 45.265.000 16.31%
2011 50.396.000 10.18%
2012 56.849.000 11.35%
2013 84.892.000 33.03%
2014 67.639.000 -25.51%
2015 69.291.000 2.38%
2016 70.210.000 1.31%
2017 70.779.000 0.8%
2018 71.056.000 0.39%
2019 60.273.000 -17.89%
2020 65.891.000 8.53%
2021 84.171.000 21.72%
2022 143.214.000 41.23%
2023 90.150.000 -58.86%
2024 61.286.000 -47.1%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Raffles Medical Group Ltd Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Raffles Medical Group Ltd Free Cashflow
Year Free Cashflow Growth
2001 -12.296.000
2002 7.053.000 274.34%
2003 2.877.000 -145.15%
2004 13.885.000 79.28%
2005 9.869.000 -40.69%
2006 17.363.000 43.16%
2007 35.633.000 51.27%
2008 33.929.000 -5.02%
2009 43.317.000 21.67%
2010 43.758.000 1.01%
2011 58.241.000 24.87%
2012 59.808.000 2.62%
2013 63.005.000 5.07%
2014 75.797.000 16.88%
2015 38.129.000 -98.79%
2016 64.357.000 40.75%
2017 66.798.000 3.65%
2018 60.121.000 -11.11%
2019 12.768.000 -370.87%
2020 69.671.000 81.67%
2021 107.243.000 35.03%
2022 170.926.000 37.26%
2023 168.787.000 -1.27%
2024 11.444.000 -1374.9%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Raffles Medical Group Ltd Operating Cashflow
Year Operating Cashflow Growth
2001 518.000
2002 10.346.000 94.99%
2003 4.771.000 -116.85%
2004 15.441.000 69.1%
2005 15.626.000 1.18%
2006 19.663.000 20.53%
2007 40.071.000 50.93%
2008 40.074.000 0.01%
2009 47.209.000 15.11%
2010 49.210.000 4.07%
2011 63.258.000 22.21%
2012 69.545.000 9.04%
2013 71.191.000 2.31%
2014 93.496.000 23.86%
2015 72.816.000 -28.4%
2016 78.854.000 7.66%
2017 82.693.000 4.64%
2018 91.528.000 9.65%
2019 111.147.000 17.65%
2020 133.146.000 16.52%
2021 160.112.000 16.84%
2022 196.225.000 18.4%
2023 189.312.000 -3.65%
2024 17.283.500 -995.33%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Raffles Medical Group Ltd Capital Expenditure
Year Capital Expenditure Growth
2001 12.814.000
2002 3.293.000 -289.13%
2003 1.894.000 -73.86%
2004 1.556.000 -21.72%
2005 5.757.000 72.97%
2006 2.300.000 -150.3%
2007 4.438.000 48.17%
2008 6.145.000 27.78%
2009 3.892.000 -57.89%
2010 5.452.000 28.61%
2011 5.017.000 -8.67%
2012 9.737.000 48.47%
2013 8.186.000 -18.95%
2014 17.699.000 53.75%
2015 34.687.000 48.98%
2016 14.497.000 -139.27%
2017 15.895.000 8.8%
2018 31.407.000 49.39%
2019 98.379.000 68.08%
2020 63.475.000 -54.99%
2021 52.869.000 -20.06%
2022 25.299.000 -108.98%
2023 20.525.000 -23.26%
2024 5.839.500 -251.49%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Raffles Medical Group Ltd Equity
Year Equity Growth
2001 91.512.000
2002 93.928.000 2.57%
2003 96.440.000 2.6%
2004 100.310.000 3.86%
2005 107.721.000 6.88%
2006 113.142.000 4.79%
2007 201.034.000 43.72%
2008 222.246.000 9.54%
2009 250.150.000 11.15%
2010 286.962.000 12.83%
2011 334.709.000 14.27%
2012 389.416.000 14.05%
2013 473.793.000 17.81%
2014 540.272.000 12.3%
2015 622.027.000 13.14%
2016 681.844.000 8.77%
2017 751.625.000 9.28%
2018 816.626.000 7.96%
2019 856.854.000 4.69%
2020 914.397.000 6.29%
2021 976.620.000 6.37%
2022 1.030.404.000 5.22%
2023 1.043.852.000 1.29%
2024 1.031.207.000 -1.23%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Raffles Medical Group Ltd Assets
Year Assets Growth
2001 114.695.000
2002 119.708.000 4.19%
2003 125.745.000 4.8%
2004 127.689.000 1.52%
2005 138.945.000 8.1%
2006 151.836.000 8.49%
2007 281.462.000 46.05%
2008 310.401.000 9.32%
2009 336.811.000 7.84%
2010 371.750.000 9.4%
2011 428.594.000 13.26%
2012 494.645.000 13.35%
2013 573.435.000 13.74%
2014 655.027.000 12.46%
2015 814.930.000 19.62%
2016 900.631.000 9.52%
2017 1.005.861.000 10.46%
2018 1.116.289.000 9.89%
2019 1.284.822.000 13.12%
2020 1.404.134.000 8.5%
2021 1.545.286.000 9.13%
2022 1.497.702.000 -3.18%
2023 1.528.230.000 2%
2024 1.518.030.000 -0.67%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Raffles Medical Group Ltd Liabilities
Year Liabilities Growth
2001 23.183.000
2002 25.780.000 10.07%
2003 29.305.000 12.03%
2004 27.379.000 -7.03%
2005 31.224.000 12.31%
2006 38.694.000 19.31%
2007 80.428.000 51.89%
2008 88.155.000 8.77%
2009 86.661.000 -1.72%
2010 84.788.000 -2.21%
2011 93.885.000 9.69%
2012 105.229.000 10.78%
2013 99.642.000 -5.61%
2014 114.755.000 13.17%
2015 192.903.000 40.51%
2016 218.787.000 11.83%
2017 254.236.000 13.94%
2018 299.663.000 15.16%
2019 427.968.000 29.98%
2020 489.737.000 12.61%
2021 568.666.000 13.88%
2022 467.298.000 -21.69%
2023 484.378.000 3.53%
2024 486.823.000 0.5%

Raffles Medical Group Ltd Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.37
Net Income per Share
0.03
Price to Earning Ratio
27.94x
Price To Sales Ratio
2.38x
POCF Ratio
17.52
PFCF Ratio
22.45
Price to Book Ratio
1.68
EV to Sales
2.07
EV Over EBITDA
14.8
EV to Operating CashFlow
14.97
EV to FreeCashFlow
19.54
Earnings Yield
0.04
FreeCashFlow Yield
0.04
Market Cap
1,67 Bil.
Enterprise Value
1,45 Bil.
Graham Number
0.62
Graham NetNet
-0.03

Income Statement Metrics

Net Income per Share
0.03
Income Quality
1.59
ROE
0.06
Return On Assets
0.04
Return On Capital Employed
0.06
Net Income per EBT
0.72
EBT Per Ebit
1.16
Ebit per Revenue
0.1
Effective Tax Rate
0.27

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.52
Operating Profit Margin
0.1
Pretax Profit Margin
0.12
Net Profit Margin
0.09

Dividends

Dividend Yield
0.03
Dividend Yield %
2.67
Payout Ratio
0.73
Dividend Per Share
0.02

Operating Metrics

Operating Cashflow per Share
0.05
Free CashFlow per Share
0.04
Capex to Operating CashFlow
0.23
Capex to Revenue
0.03
Capex to Depreciation
0.62
Return on Invested Capital
0.05
Return on Tangible Assets
0.04
Days Sales Outstanding
76.95
Days Payables Outstanding
229.63
Days of Inventory on Hand
12.38
Receivables Turnover
4.74
Payables Turnover
1.59
Inventory Turnover
29.49
Capex per Share
0.01

Balance Sheet

Cash per Share
0,17
Book Value per Share
0,55
Tangible Book Value per Share
0.54
Shareholders Equity per Share
0.54
Interest Debt per Share
0.06
Debt to Equity
0.1
Debt to Assets
0.07
Net Debt to EBITDA
-2.2
Current Ratio
1.2
Tangible Asset Value
1,01 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
859715000
Working Capital
0,08 Bil.
Intangibles to Total Assets
0.01
Average Receivables
0,15 Bil.
Average Payables
0,21 Bil.
Average Inventory
11506000
Debt to Market Cap
0.06

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Raffles Medical Group Ltd Dividends
Year Dividends Growth
2003 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Raffles Medical Group Ltd Profile

About Raffles Medical Group Ltd

Raffles Medical Group Ltd provides integrated private healthcare services primarily in Singapore, Greater China, Vietnam, Cambodia, and Japan. The company operates through Healthcare Services, Hospital Services, and Investment Holdings segments. Its flagship hospital is the Raffles Hospital, a tertiary care hospital that offers cancer, children and women care, Chinese medicine, counselling, dental, dialysis, diabetes and endocrinology, ear, nose, throat, eye, fertility, heart, internal medicine, neuroscience, pain management, rehabilitation, orthopedic, skin and aesthetics, surgery, nuclear medicine, and urology services. The company also offers emergency services, family medicine services, health screening, and various multi-disciplinary specialist clinic services. In addition, it trades in pharmaceutical and nutraceutical products, and diagnostic equipment; provides advisory and consultancy services, and develops IT solutions; and engages in research and experimental development on biotechnology, and life and medical science. Raffles Medical Group Ltd was founded in 1976 and is based in Singapore.

CEO
Dr. Choon Yong Loo
Employee
2.900
Address
585 North Bridge Road
Singapore, 188770

Raffles Medical Group Ltd Executives & BODs

Raffles Medical Group Ltd Executives & BODs
# Name Age
1 Ms. Won Lein Ng
Chief Financial Officer
70
2 Dr. Kenneth Wu
Chief Operating Officer of Singapore Healthcare
70
3 Joanna Lee
Senior Manager of Communications
70
4 Mr. Quek Sin Kwok
Chief Digital Officer
70
5 Dr. Choon Yong Loo
Executive Chairman & Chief Executive Officer
70
6 Dr. Vincent Chia
Managing Director of Raffles China Healthcare
70
7 Mr. Kah Ling Teo
Chief Information Officer
70
8 Mr. Soo Nan Tan
Executive & Non-Independent Director
70
9 Dr. Qinghui Lu
Executive & Non-Independent Director
70
10 Mr. Darren Tan
Chief Investment Officer
70

Raffles Medical Group Ltd Competitors